演題詳細

ポスター / Poster

ポスター 47 (Poster 47) :細胞療法

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F エメラルドABCD)
座長・司会
三浦 康生 (Yasuo Miura):1
1:京都大学医学部附属病院 輸血細胞治療部
 
前へ戻る

Vaccination with irradiated induced pluripotent stem cells elicits substantial antitumor immunity

演題番号 : PS-1-358

井上 博之 (Hiroyuki Inoue):1,2、渡邊 あゆみ (Ayumi Watanabe):1、坂本 千香 (Chika Sakamoto):1、成澤 慈 (Megumi Narusawa):1、宮本 将平 (Shohei Miyamoto):1、井上 誠 (Makoto Inoue):3、高山 浩一 (Koichi Takayama):2、長谷川 護 (Mamoru Hasegawa):3、中西 洋一 (Yoichi Nakanishi):2、谷 憲三朗 (Kenzaburo Tani):1

1:Molecular Clinical Genetics, Medical Institute of Bioregulation, Kyushu University, Japan、2:Research Institute for Diseases of the Chest, Fukuoka, Japan、3:DNAVEC Corporation

 

Development of novel therapeutic modality targeting cancer stem cells (CSCs) has recently been identified and holds great promise for cancer treatment. It was shown that CSCs and normal stem cells including embryonic stem (ES) cells have the similarities in antigenicity as well as properties in self-renewal, multilineage differentiation. Besides, induced pluripotent stem (iPS) cells are recently discovered to share many characteristics with ES cells but to circumvent ethical issues. We therefore hypothesized that therapeutic cell vaccination using irradiated iPS cells genetically engineered to produce GM-CSF (ir.iPS/GM) would generate an antitumor immunity in a syngeneic mouse model. It was shown that, regardless of irradiation, iPS/GM cells produced abundant GM-CSF in vitro and retained their stemness in terms of antigenicity and morphology compared with unmodified iPS cells. Next, syngeneic C57BL/6 mice that repeatedly vaccinated with ir.iPS/GM cells significantly inhibited the outgrowth of poorly immunogenic LLC mouse lung tumors without serious adverse events. In vivo depletion assays demonstrated that both CD4+ T cells and CD8+ T cells contribute to the ir.iPS/GM cells-triggered antitumor effects. Furthermore, substantial antitumor effects against pre-established LLC tumors were also observed in a therapeutic vaccination model using ir.iPS/GM cells.In conclusion, we for the first time show that iPS cells-based tumor immunotherapy is effective to control tumor development, warranting further investigation as a promising alternative for novel cancer immunotherapy.

前へ戻る